プロバイオティクスと健康に関するジャーナル
オープンアクセス

概要

Bifidobacterium breve M4A and Bifidobacterium longum subsps. longum FA1 Reduced Weight Gain and Hepatic Lipid Droplets in Young Mice Fed High-Fat

Mustafa Alsharafani*, Martin Roderfeld, Elke Roeb and Michael Krawinkel

Among commensal bacteria, Bifidobacteria (B) is one of the most numerous probiotics in the mammalian gut. The goal of the study was to evaluate the in vivo anti-obesity effect of B. breve M4A and B. longum subsp. longum FA1 in young mice fed a high-fat diet (HFD). Three (male mice C57BL/6JRj) groups, the model HFD group and treatment (HFD-FA1 and HFD-M4A) groups were fed an HFD to induce obesity. After feeding the mice a HFD for six weeks, animals receiving B. breve M4A and B. longum subsp. longum FA1 had significantly lower (p<0.01) weight gain compared to mice fed a high-fat diet only. Mice fed B. breve M4A supplemented with 0.3% yeast extract and 3% glucose exhibited significantly lower serum triglycerides (p<0.05) compared with the HFD group. The daily consumption (2.9 × 106 CFU/day) of B. longum subps. longum FA1 and (4.1 × 106 CFU/day) B. breve M4A (p<0.01) significantly increased the amount of bifidobacteria and lactic acid bacteria in the cecal content. This study showed that Bifidobacterium species reduced weight gain and hepatitis lipid droplets. Thus, bifidobacteria supplementation may be one mean for reducing obesity and related chronic Non-communicable diseases.